Table 2.
Cox's proportional hazards regression model for mortality in the PMI cohort.
| Coefficient | SE | Wald | df | Significance | Hazard Ratio | 95% CI for Hazard Ratio | |
| Age | 0.018 | 0.016 | 1.40 | 1 | 0.237 | 1.02 | 0.99–1.05 |
| Gender | 0.587 | 0.270 | 4.71 | 1 | 0.030 | 1.80 | 1.06–3.06 |
| ACE inhibitor (No/Yes) | 0.235 | 0.229 | 1.06 | 1 | 0.303 | 1.27 | 0.81–1.98 |
| LVEF (1–4 days post-MI) | -0.013 | 0.011 | 1.48 | 1 | 0.224 | 0.99 | 0.97–1.01 |
| Log10 NTproBNP* | 1.55 | 0.409 | 14.3 | 1 | <0.001 | 4.70 | 2.11–10.5 |
| Log10 peak creatine kinase* | 1.11 | 0.338 | 10.8 | 1 | 0.001 | 3.04 | 1.56–5.88 |
| Creatinine clearance | -0.900 | 0.384 | 5.49 | 1 | 0.019 | 0.406 | 0.19–0.86 |
| Ethnicity (European v non-European) | 1.05 | 0.597 | 3.11 | 1 | 0.078 | 2.86 | 0.89–9.21 |
| Type 2 Diabetes | 0.847 | 0.602 | 1.98 | 1 | 0.159 | 2.33 | 0.72–7.59 |
| UCP2 G-866A genotype | 4.91 | 2 | 0.086 | ||||
| GG v AA | 1.64 | 0.747 | 4.79 | 1 | 0.029 | 5.13 | 1.19–22.2 |
| GG v GA | 1.16 | 0.684 | 2.89 | 1 | 0.089 | 3.19 | 0.841–12.2 |
| Diabetes × UCP2 genotype | 6.92 | 2 | 0.031 | ||||
| Diabetes × UCP2 genotype(GG v AA) | 1.52 | 0.725 | 4.40 | 1 | 0.036 | 4.59 | 1.10–18.9 |
| Diabetes × UCP2 genotype(GG v GA) | 2.09 | 0.826 | 6.40 | 1 | 0.011 | 8.06 | 1.60–40.0 |
* Hazard Ratio represents the change in risk for every 10-fold increase in measurement level.